Cabaletta Bio, Inc. - CABA STOCK NEWS

Cabaletta Bio reported promising results from its DesCAARTes™ Phase 1 clinical trial regarding DSG3-CAART for treating mucosal pemphigus vulgaris. As of August 17, no dose-limiting toxicities or significant adverse events occurred in the second cohort, which received 100 million cells. DSG3-CAART persistence was confirmed in all three patients during the 28 days post-infusion. The trial has now moved to a third cohort, dosing 500 million cells, with safety and efficacy data expected in Q4 2021. The company aims to develop targeted therapies for autoimmune diseases while avoiding generalized immunosuppression.

Cabaletta Bio, Inc. (Nasdaq: CABA) reported Q2 2021 financial results and updates on its clinical trials. The company is progressing with the DesCAARTes™ trial for DSG3-CAART, expecting to release safety data for additional patient cohorts in Q3 and Q4 2021. They plan to submit an IND for MuSK-CAART in H2 2021 and have requested a pre-IND meeting for PLA2R-CAART. Cash and equivalents stood at $102.8 million as of June 30, 2021. R&D expenses increased to $7.9 million from $5.3 million year-over-year.

Cabaletta Bio, Inc. (CABA) recently appointed Dr. Scott Brun to its Board of Directors. Dr. Brun, with over 20 years in drug development, previously held leadership roles at AbbVie and Abbott Laboratories. His expertise in autoimmune diseases aligns with Cabaletta's goal to advance its lead program, DSG3-CAART, targeting mucosal pemphigus vulgaris. Dr. Brun will also serve on the Audit and Nominating Committees. His appointment follows the resignation of Dr. Brian Daniels, who contributed to the board since 2018. The company aims to enhance shareholder value with this strategic addition.

On May 27, 2021, Cabaletta Bio, a clinical-stage biotechnology company focused on engineered T cell therapies, announced that CEO Steven Nichtberger will participate in a fireside chat at the Jefferies Healthcare Conference on June 3, 2021, at 4:30 p.m. ET. A live webcast will be available on the company’s website, with a replay accessible for 90 days post-event. Cabaletta's lead candidate, DSG3-CAART, is in a Phase 1 trial for treating mucosal pemphigus vulgaris, with Fast Track Designation from the FDA since May 2020.

Cabaletta Bio, Inc. reported promising initial safety data from the DesCAARTes™ trial for DSG3-CAART, showing no dose-limiting toxicities (DLTs) or adverse events in the first cohort. The company plans to advance two new programs: PLA2R-CAART for PLA2R-associated membranous nephropathy and MuSK-CAART for myasthenia gravis, with IND submissions anticipated in the latter half of 2021. Financially, Cabaletta reported a cash position of $102 million as of March 31, 2021, enabling operations through Q4 2022, despite rising R&D expenses of $6.6 million, up from $4.6 million in Q1 2020.

Cabaletta Bio (CABA) announced positive acute safety data from the first cohort of its Phase 1 DesCAARTes™ clinical trial for DSG3-CAART, targeting mucosal-dominant pemphigus vulgaris. As of April 30, 2021, no dose limiting toxicities (DLTs) or clinically relevant adverse events were reported among the three patients dosed. The company anticipates initiating the second dose cohort after confirming safety data from the first cohort. Acute safety results for the second and third cohorts are expected in Q3 and Q4 2021. A conference call is scheduled for today at 8:30 a.m. ET to discuss these results.

Cabaletta Bio is a clinical-stage biotechnology firm focused on engineered T cell therapies for patients with B cell-mediated autoimmune diseases. On April 14, 2021, at 3:00 p.m. ET, CEO Steven Nichtberger will participate in a fireside chat at the 20th Annual Needham Healthcare Conference. The live webcast will be accessible on the company’s website and will remain available for replay for 90 days. The lead product candidate, DSG3-CAART, targets mucosal pemphigus vulgaris and has received Fast Track Designation from the FDA.

Cabaletta Bio, Inc. (CABA) reported its financial results for Q4 and FY 2020, highlighting significant milestones in its clinical trials. The company successfully dosed the first patient in a Phase 1 trial for DSG3-CAART, targeting mucosal pemphigus vulgaris, without dose limiting toxicities. Financially, R&D expenses increased to $21.4 million in 2020, up from $11.7 million in 2019. The company ended 2020 with $108.7 million in cash, down from $136.2 million a year earlier, ensuring funding through Q3 2022. Key milestones are anticipated in 2021, including additional trial data and an IND submission for MuSK-CAART.

Cabaletta Bio, Inc. (Nasdaq: CABA), a biotechnology firm specializing in engineered T cell therapies for B cell-mediated autoimmune diseases, will participate in two investor conferences in March 2021. The first is the Cowen & Co. 41st Annual Health Care Conference on March 3, where CEO Steven Nichtberger will engage in a cell therapy panel. The second is the H.C. Wainwright Global Life Sciences Conference on March 9, featuring a pre-recorded fireside chat. The discussion will be available on-demand post-conference on the company’s website for 90 days.